Using variation between countries to estimate demand for Cochrane reviews when access is free: a cost-benefit analysis.

Abstract

Cochrane reviews are currently of limited use as many healthcare professionals and patients have no access to them. Most member states of the Organisation for Economic Co-operation and Development (OECD) choose not to pay for nationwide access to the reviews, possibly uncertain whether there is enough demand to warrant the costs of a national subscription. This study estimates the demand for review downloads and summary views under free access across all OECD countries. The study employs a retrospective design in analysing observational data of web traffic to Cochrane websites in 2014. Specifically, we model for each country downloads of Cochrane reviews and views of online summaries as a function of free access status and alternative sources of variation across countries. The model is then used to estimate demand if a country with restricted access were to purchase free access. We use these estimates to perform a cost-benefit analysis. For one group of eight OECD countries, the additional downloads under free access are estimated to cost between US$4 and more than US$20 each. Three countries are expected to save money under free access, as existing institutional subscriptions would no longer be needed. For the largest group of 17 member states, free access is estimated to cost US$0.05-US$2 per additional review download. On average, the increase in review downloads does not appear to be associated with a decrease in the number of summary views. Instead, translations of plain-language summaries into national languages can serve as an additional strategy for dissemination. We estimate that free access would cost less than US$2 per additional download for 20 of the 28 OECD countries without national subscriptions, including Canada, Germany and Israel. These countries may be encouraged by our findings to provide free access to their citizens.